Zogenix, Inc. (ZGNX) is Perceptive Advisors LLC’s 5th Largest Position

Perceptive Advisors LLC boosted its position in Zogenix, Inc. (NASDAQ:ZGNX) by 8.2% in the 4th quarter, Holdings Channel reports. The firm owned 3,970,357 shares of the company’s stock after acquiring an additional 300,000 shares during the quarter. Zogenix accounts for about 5.3% of Perceptive Advisors LLC’s portfolio, making the stock its 5th largest position. Perceptive Advisors LLC owned 0.12% of Zogenix worth $160,799,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Eagle Asset Management Inc. purchased a new stake in Zogenix in the 4th quarter valued at $39,750,000. VHCP Management II LLC purchased a new stake in Zogenix in the 3rd quarter valued at $31,792,000. Carillon Tower Advisers Inc. purchased a new stake in Zogenix in the 4th quarter valued at $27,776,000. BlackRock Inc. grew its holdings in Zogenix by 30.6% in the 4th quarter. BlackRock Inc. now owns 2,656,444 shares of the company’s stock valued at $106,389,000 after buying an additional 622,668 shares in the last quarter. Finally, Farallon Capital Management LLC grew its holdings in Zogenix by 165.6% in the 4th quarter. Farallon Capital Management LLC now owns 850,000 shares of the company’s stock valued at $34,043,000 after buying an additional 530,000 shares in the last quarter.

In other news, EVP Bradley S. Galer bought 1,346 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were purchased at an average price of $36.59 per share, with a total value of $49,250.14. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.60% of the stock is currently owned by corporate insiders.

Zogenix, Inc. (ZGNX) opened at $45.00 on Monday. The firm has a market capitalization of $1,541.36, a price-to-earnings ratio of -9.70 and a beta of 1.57. Zogenix, Inc. has a twelve month low of $8.50 and a twelve month high of $45.85.

Zogenix (NASDAQ:ZGNX) last posted its earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.17). Zogenix had a negative return on equity of 81.65% and a negative net margin of 309.76%. During the same period last year, the business posted ($0.95) EPS. analysts expect that Zogenix, Inc. will post -3.12 EPS for the current year.

A number of research firms have recently weighed in on ZGNX. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a report on Sunday, March 4th. Mizuho reiterated a “buy” rating and set a $51.00 price target on shares of Zogenix in a report on Wednesday, March 7th. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. Finally, JMP Securities began coverage on Zogenix in a report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Zogenix currently has a consensus rating of “Buy” and a consensus target price of $46.40.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://weekherald.com/2018/03/12/zogenix-inc-zgnx-is-perceptive-advisors-llcs-5th-largest-position.html.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply